Casdin entities boost Standard BioTools (LAB) stake with open‑market buys
Rhea-AI Filing Summary
Standard BioTools director and 10% owner entities associated with Eli Casdin reported a series of open‑market purchases of common stock. Casdin Partners Master Fund, L.P. bought 200,000 shares on August 22, 2025 at $1.2634, 200,000 shares on August 25 at a weighted average $1.2409, and 125,000 shares on August 26 at $1.2635.
After these trades, the Master Fund held 60,275,000 shares indirectly for the reporting group. Separate positions include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares held by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares held by Casdin Private Growth Equity Fund, L.P.
Positive
- None.
Negative
- None.
Insights
Casdin-affiliated funds increased their Standard BioTools equity stake through open‑market purchases.
Several Casdin-managed entities, which are directors and significant owners of Standard BioTools, reported open‑market purchases of common stock around $1.24–$1.26 per share. The trades were executed by Casdin Partners Master Fund, L.P., with indirect beneficial interests across related investment vehicles and Eli Casdin.
Post‑transaction, the Master Fund is shown with 60,275,000 shares, while other Casdin funds and Eli Casdin hold additional direct and indirect positions. The filing emphasizes that each reporting person only acknowledges beneficial ownership to the extent of its pecuniary interest, so actual economic exposure aligns with these disclosed interests.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, $0.001 par value per share | 125,000 | $1.2635 | $158K |
| Purchase | Common Stock, $0.001 par value per share | 200,000 | $1.2409 | $248K |
| Purchase | Common Stock, $0.001 par value per share | 200,000 | $1.2634 | $253K |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
Footnotes (1)
- The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2311 to $1.2475. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. The securities are owned directly by Eli Casdin. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
